REGN News and Press, Regeneron Pharmaceuticals Inc. From 01/09/24

2024-01-09 13:00:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for REGN on January 9, 2024 01:00PM ET. The previous analyst recommendation was Underperform. REGN was trading at $894.06 at issue of the analyst recommendation. The overall analyst consensus :...

2024-01-09 01:07:03 ET Summary Xeris Biopharma Holdings focuses on developing and commercializing therapies in endocrinology, neurology, and gastroenterology using their proprietary formulation platforms. Their formulation platforms, XeriSol and XeriJect, address limitations of aq...

2024-01-08 20:25:04 ET Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference Call January 08, 2024, 5:15 PM ET Company Participants Chris Schott - JPMorgan Leonard Schleifer - Board Co-Chair, President and Chief Executive Officer George...

2024-01-08 18:51:51 ET Summary Regeneron Pharmaceuticals, Inc.'s shares have risen over 25% in recent months, reaching over $910 per share - a premium explained partly by share buybacks. The company's market cap is around $100 billion, despite generating substantially lower revenu...

2024-01-08 14:06:31 ET Disclosing its preliminary financials for Q4 2023, Regeneron Pharmaceuticals ( NASDAQ: REGN ) announced Monday that it intends to recognize ~$1.34B as U.S. net product sales from its blockbuster eye disease therapy Eylea during the quarter. Meanwhile, its ...

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries Canada NewsWire Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous ...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open. The Company will ho...

2024-01-04 08:30:00 ET Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been able to pull that off (and then some) in the past half de...

2024-01-03 06:43:17 ET More on Alvotech, Regeneron, etc. Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript) Alvotech: Biosimilars Portfolio Opportunity Is High Risk Alvotech (ALVO) Q3 2023 Earnings Call Transc...